Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advances

Chronic spontaneous urticaria (CSU) is a debilitating skin disease characterized by intensely itchy wheals, angioedema, or both. Symptoms recur spontaneously, on a near-daily basis, over >6 weeks; many patients experience flare-ups over several years and, consequently, reduced quality of life...

Descripción completa

Detalles Bibliográficos
Autores: Kaplan, Allen P., Lebwohl, Mark, Giménez Arnau, Anna Maria, Hide, Michihiro, Armstrong, April W., Maurer, Marcus
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/55824
Acceso en línea:http://hdl.handle.net/10230/55824
http://dx.doi.org/10.1111/all.15603
Access Level:acceso abierto
Palabra clave:IgE
Angioedema
Dermatology
Mast cells
Urticaria
id ES_edc92aaec381369a6c346b5efc2bb1bb
oai_identifier_str oai:recercat.cat:10230/55824
network_acronym_str ES
network_name_str España
repository_id_str
spelling Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advancesKaplan, Allen P.Lebwohl, MarkGiménez Arnau, Anna MariaHide, MichihiroArmstrong, April W.Maurer, MarcusIgEAngioedemaDermatologyMast cellsUrticariaChronic spontaneous urticaria (CSU) is a debilitating skin disease characterized by intensely itchy wheals, angioedema, or both. Symptoms recur spontaneously, on a near-daily basis, over >6 weeks; many patients experience flare-ups over several years and, consequently, reduced quality of life. Differences between the inflammatory profiles of the skin of CSU patients (wheals and nonlesional sites) and healthy controls indicate that key drivers such as mast cells, eosinophils, and basophils interact, release vasoactive mediators, and prime the skin, leaving patients predisposed to symptoms. Many cytokines and chemokines involved in these inflammatory networks and their corresponding intracellular signaling cascades have been identified. These insights informed the development of therapies such as omalizumab, dupilumab, and Bruton's tyrosine kinase (BTK) inhibitors, marking a renewed focus on pathogenesis in CSU clinical research. Despite progress, current therapies provide symptomatic control but do not appear to redress the inflammatory balance in the skin permanently. A deeper understanding of CSU pathogenesis will permit a more targeted approach to developing novel treatments with curative intent. Here, we review what is known about the pathogenesis of CSU and consider how this can be used to identify rational targets to improve patient care further.Wiley202320232023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/55824http://dx.doi.org/10.1111/all.15603reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License http://creativecommons.org/licenses/by-nc/4.0/, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.http://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/558242026-05-29T05:05:01Z
dc.title.none.fl_str_mv Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advances
title Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advances
spellingShingle Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advances
Kaplan, Allen P.
IgE
Angioedema
Dermatology
Mast cells
Urticaria
title_short Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advances
title_full Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advances
title_fullStr Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advances
title_full_unstemmed Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advances
title_sort Chronic spontaneous urticaria. Focus on pathophysiology to unlock treatment advances
dc.creator.none.fl_str_mv Kaplan, Allen P.
Lebwohl, Mark
Giménez Arnau, Anna Maria
Hide, Michihiro
Armstrong, April W.
Maurer, Marcus
author Kaplan, Allen P.
author_facet Kaplan, Allen P.
Lebwohl, Mark
Giménez Arnau, Anna Maria
Hide, Michihiro
Armstrong, April W.
Maurer, Marcus
author_role author
author2 Lebwohl, Mark
Giménez Arnau, Anna Maria
Hide, Michihiro
Armstrong, April W.
Maurer, Marcus
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv IgE
Angioedema
Dermatology
Mast cells
Urticaria
topic IgE
Angioedema
Dermatology
Mast cells
Urticaria
description Chronic spontaneous urticaria (CSU) is a debilitating skin disease characterized by intensely itchy wheals, angioedema, or both. Symptoms recur spontaneously, on a near-daily basis, over >6 weeks; many patients experience flare-ups over several years and, consequently, reduced quality of life. Differences between the inflammatory profiles of the skin of CSU patients (wheals and nonlesional sites) and healthy controls indicate that key drivers such as mast cells, eosinophils, and basophils interact, release vasoactive mediators, and prime the skin, leaving patients predisposed to symptoms. Many cytokines and chemokines involved in these inflammatory networks and their corresponding intracellular signaling cascades have been identified. These insights informed the development of therapies such as omalizumab, dupilumab, and Bruton's tyrosine kinase (BTK) inhibitors, marking a renewed focus on pathogenesis in CSU clinical research. Despite progress, current therapies provide symptomatic control but do not appear to redress the inflammatory balance in the skin permanently. A deeper understanding of CSU pathogenesis will permit a more targeted approach to developing novel treatments with curative intent. Here, we review what is known about the pathogenesis of CSU and consider how this can be used to identify rational targets to improve patient care further.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/55824
http://dx.doi.org/10.1111/all.15603
url http://hdl.handle.net/10230/55824
http://dx.doi.org/10.1111/all.15603
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423560398733312
score 15,81155

Similares en LA Referencia